Yaz Blood Clots, Deep Vein Thrombosis (DVT)Posted in Product Liability Keith Belt
Pharmaceutical products containing drospirenone may pose life threatening risks to certain segment of user’s, national class action product liability attorney Keith T. Belt says
The FDA has announced that two new studies have revealed a higher risk of blood clots in women taking drospirenone-containing birth control pills. While Yaz blood clots have also been a known side effect of the birth control drug, the new studies suggest that women taking Yaz, Yasmin, Ocella and other drospirenone contraceptives have up to three times the risk of developing venous thromboembolism (VTE), when compared to woman taking contraceptives containing levonorgestrel. Because the manufacturer failed to warn patients about this increased risk of Yaz blood clots, which may also include deep vein thrombosis and pulmonary embolism, patients who developed these Yaz side effects may have legal recourse.
The new information regarding Yaz blood clots adds to growing concerns regarding the health risks associated with Yaz, Yasmin and Ocella. These birth control pills contain a different type of hormone known as drospirenone, and can increase users’ potassium levels. In addition to Yaz blood clots, serious problems which can result from increased potassium levels may include:
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Heart attack
- Gallbladder disease
- Cardiac death
- Venous thromboembolism (VTE)
Deep vein thrombosis, venous thromboembolism and pulmonary embolism are three types of Yasmin blot clots associated with use of the drug and its equivalents. Signs which may indicate Yaz blood clots include shortness of breath, severe chest pain and persistent leg pain.